Wells Fargo & Company »

Acrivon Therapeutics shares owned by Wells Fargo & Company

Quarter-by-quarter ownership of Acrivon Therapeutics (ACRV) shares owned by Wells Fargo & Company from 13F filings

Historical chart of Wells Fargo & Company investment in Acrivon Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Acrivon Therapeutics held by Wells Fargo & Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Acrivon Therapeutics by Wells Fargo & Company

Quarter filed Position value Share count Share price at filing
2023-12-31 $13k 2.7k 4.92
2023-09-30 $21k 2.2k 9.56
2023-06-30 $43k 3.3k 12.96

More positions owned by Wells Fargo & Company

Microsoft Corporation Put Option (MSFT)
Apple (AAPL)
Ishares Tr Russell 2000 Etf (IWM)
Spdr S&p 500 Etf Tr Tr Unit Put Option (SPY)
Invesco Qqq Tr Unit Ser 1 Put Option (QQQ)
Ishares Tr Core S&p500 Etf (IVV)
Amazon Put Option (AMZN)
Vanguard Index Fds Mid Cap Etf Put Option (VO)
Ishares Tr Core Us Aggbd Et (AGG)
Ishares Tr Core S&p Ttl Stk (ITOT)
UnitedHealth Call Option (UNH)
JPMorgan Chase & Co. Put Option (JPM)
Ishares Tr Core Msci Eafe (IEFA)
Ishares Tr Iboxx Hi Yd Etf (HYG)
Johnson & Johnson (JNJ)

View all positions for Wells Fargo & Company

Top funds holding Acrivon Therapeutics

RA Capital Management
Perceptive Advisors
Citadel Advisors
Wellington Management Company
Marshall Wace
Vanguard Group
NEA Management Company
Federated Investors
DAFNA Capital Management
Charles Schwab Investment Management
Exchange Traded Concepts
Jacobs Levy Equity Management
Jpmorgan Chase & Co
D. E. Shaw & Co
Barclays

View all funds holding Acrivon Therapeutics